Generic Name: pralsetinib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Experimental Code: BLU-667
Gavreto is a kinase inhibitor approved for the treatment of metastatic non-small-cell lung cancer with RET gene fusions and metastatic thyroid cancer with RET mutations or fusions.
Gavreto blocks the RET protein, which plays a role in cell proliferation. Mutations and fusions in the RET gene can drive the development of cancer. The ARROW trial showed that Gavreto shrank tumors in 57% of people with previously treated non-small-cell lung cancer with RET fusions and in 70% of those being treated for the first time. The overall response rate was 60% for people with previously treated RET-mutant medullary thyroid cancer and 89% for those with refractory RET fusion positive thyroid cancer. Gavreto was first approved in September 2020.
Gavreto is taken as a capsule once daily on an empty stomach.
The most common adverse reactions include fatigue, constipation, muscle pain, hypertension, elevated ALT liver enzymes and other laboratory abnormalities. Gavreto can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Potential serious side effects include lung problems, severe hypertension, liver toxicity, severe bleeding and slow wound healing. Gavreto can cause fetal harm if used during pregnancy.
For More Info: https://www.gene.com/download/pdf/gavreto_patientinfo.pdf
Patient Assistance Program Info: http://www.yourblueprint.com/
Last Reviewed: December 1, 2020